Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

Tetraploid acute promyelocytic leukemia with double translocation t (15,17) PML/RARA: the first case report in Croatia and Europe (CROSBI ID 291710)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Periša Vlatka, Laslo Dorian, Franić-Šimić Ivana, Sinčić-Petričević Jasminka Tetraploid acute promyelocytic leukemia with double translocation t (15,17) PML/RARA: the first case report in Croatia and Europe // IRDR, Volume 10 Issue (2021), 48-51. doi: 10.5582/irdr.2020.03146

Podaci o odgovornosti

Periša Vlatka, Laslo Dorian, Franić-Šimić Ivana, Sinčić-Petričević Jasminka

engleski

Tetraploid acute promyelocytic leukemia with double translocation t (15,17) PML/RARA: the first case report in Croatia and Europe

Acute promyelocytic leukemia (APL) is characterized by the translocation t (15 ; 17) (q22 ; q21) cytogenetic abnormality in the majority of cases. In most of the cases the cells of APL have normal, diploid karyotype. There are very few cases presented with very rare tetraploid karyotype with double translocation t(15 ; 17)(q22 ; q12). We report the first case of tetraploid APL with double translocation t(15, 17) in Europe. A 66-year old male patient presented with dyspnea and unexplained dental bleeding. Blood work showed a white blood cell count of 1x109/L, hemoglobin was 124 g/ L, platelet count was 61x109/L and fibrinogen level was low (1.4 g/L). Cytogenetics showed a tetraploid karyotype. Fluorescence in situ hybridization analysis proved existence of clonal cells with translocation t (15, 17) in 15% of metaphase nuclei and tetraploid subclonal cells with the same translocation in 70% of metaphase nuclei. Findings were consistent with APL, tetraploid variant and the patient started all-trans retinoic acid (ATRA) treatment. The patient achieved complete remission in 2 months and completed three consolidation therapy cycles with ATRA, idarubicin or mitraxontrate. Currently, the patient is undergoing maintenance therapy with ATRA, 6-mercaptopurine and weekly methotrexate.

PML-RARA ; acute promyelocytic leukemia ; all trans-retinoic acid (ATRA) ; tetraploid

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

Volume 10 Issue

2021.

48-51

objavljeno

2186-3644

2186-361X

10.5582/irdr.2020.03146

Povezanost rada

Kliničke medicinske znanosti

Poveznice